Global Oncology Academy

Keeping Pace with Immunotherapy Advances in Non-Small Cell Lung Cancer: Global Lessons

Keeping Pace with Immunotherapy Advances in Non-Small Cell Lung Cancer: Global Lessons

Improve your understanding of the use of first-line immunotherapy in patients with Non-Small Cell Lung Cancer.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This article presents a summary of current and emergent oncology clinical data with a focus on the role of immune checkpoint inhibitors and appropriate first-line therapy options in metastatic non-small cell lung cancer (NSCLC). This succinct tutorial also examines the function of tumor mutational burden (TMB) and how to define the relationship between PD-L1 expression and the appropriate selection of an anti-PD-1/L1 immune checkpoint inhibitor for advanced NSCLC.

    Findings from the clinical trial KEYNOTE-189 are discussed within this CME activity. We would like to bring to your attention that an updated analysis from KEYNOTE-189 has recently been published. Access to that publication can be found through the following link:

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


    Gilberto de Lima Lopes Junior, MD, MBA, FAMS
    Associate Professor of Clinical Medicine
    Medical Director for International Programs
    Associate Director for Global Oncology
    Co-Leader, Lung Cancer Site Disease Group
    Sylvester Comprehensive Cancer Center at the University of Miami and
    the Miller School of Medicine 
    Miami, FL

    Consulting Fees: AstraZeneca, Boehringer Ingelheim, E.R. Squibb Sons, LLC, Janssen, Pfizer
    Research Funding:
    AstraZeneca; (To Institution) AstraZeneca, Bavarian Nordic, Blueprint Medicines, EMD Serono, G1 Therapeutics, Merck Sharp & Dohme, Novartis, Tesaro

    Kai He MD, PhD
    Assistant Professor
    The Ohio State University Wexner Medical Center
    Columbus, OH

    Consulting Fees: BMS, Mirati
    Contracted Research: Adaptimmune, Amgen, BMS, GSK, Iovance, Mirati

    Jyoti D. Patel, MD, FASCO
    Professor of Medicine
    Northwestern University
    Robert H. Lurie Comprehensive Cancer Center
    Chicago, IL

    Consulting Fees: AbbVie, Astra Zeneca, Genentech, Takeda
    Research support: BMS for University of Chicago

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Jorge Bacigalupo has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Brian P. McDonough, MD FAAFP has nothing to disclose.
    • Tricia O’Leary has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the appropriate first-line therapy options for patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) based on current and emergent clinical data regarding the role of immune checkpoint inhibitors.
    • Discuss the role of tumor mutational burden (TMB) in patients with metastatic NSCLC and its association with the efficacy of immune checkpoint inhibitors in various regimens.
    • Define the relationship between PD-L1 expression and appropriate selection of an anti-PD-1/L1 immune checkpoint inhibitor for advanced NSCLC.
  • Target Audience

    This activity is designed to meet the educational needs of Thoracic Medical Oncologists, Medical Oncologists, Pathologists, Nurse Practitioners, Physician Assistants, and Registered Nurses treating oncology patients.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions.  Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”. 

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free